Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status

Rolof G.P. Gijtenbeek; Kim de Jong; Ben J.W. Venmans; Femke H.M. van Vollenhoven; Anneke Ten Brinke; Anthonie J. Van der Wekken; Wouter H. van Geffen

Journal ArticleOPEN ACCESS

Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status

Gijtenbeek R
de Jong K
Venmans B
et al.

Cochrane Database of Systematic Reviews (2019) 2019(8)

DOI: 10.1002/14651858.CD013382

2Citations

17Readers

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To identify the best first-line therapy for advanced lung cancer in patients with performance status 2 without a targetable mutation or with an unknown mutation status.

Cite

CITATION STYLE

APA

Gijtenbeek, R. G. P., de Jong, K., Venmans, B. J. W., van Vollenhoven, F. H. M., Brinke, A. T., Van der Wekken, A. J., & van Geffen, W. H. (2019). Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status. Cochrane Database of Systematic Reviews, 2019(8). https://doi.org/10.1002/14651858.CD013382

Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status

Abstract

Cite

Register to see more suggestions